MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence

Recruiting now

Conditions studied: Glioma

In brief

This registry aims to collect clinical, molecular and radiologic data including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Key facts

Study ID

NCT04215211

Run by

The First Affiliated Hospital of Zhengzhou University

People needed

2500

Starts

2017-01-01

Expected to finish

2027-06-01

Last updated by the study team

2021-02-08

Who can join

Age: 1 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have radiologically and histologically confirmed diagnosis of primary glioma
• Life expectancy of greater than 3 months
• Must receive tumor resection
• Signed informed consent

You may not qualify if…

• No gliomas
• No sufficient amount of tumor tissues for detection of molecular pathology
• Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices
• Patients who are pregnant or breast feeding
• Patients who are suffered from severe systematic malfuctions

Where it is running

• Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.